Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Top Supplement Stories 2013: POM Saga, Spiked Products, GMPs

This article was originally published in The Tan Sheet

Executive Summary

Experts’ predictions for tighter GMP enforcement and the federal government shutdown’s effect on industries regulated by CFSAN joined the POM-FTC litigation and Pfizer’s work to identify bad actors making ED-spiked supplements as top supplement sector stories in “The Tan Sheet” during 2013.

You may also be interested in...



FDA Shutdown Lands Hard On CFSAN-Regulated Industries

The federal shutdown interrupts FDA’s increasing enforcement against firms marketing violative supplement products in addition to slowing drug application evaluations and facility inspections. FDA would retain 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”

Trade Groups, Emord Rip FTC Interpretation Of POM Wonderful Ads

An amici curiae brief filed in the POM Wonderful case by CHPA and CRN criticizes FTC for relying “on its own ‘expertise’ to determine the meaning of ambiguous advertisements.” A separate brief by attorney Jonathan Emord says FTC is creating unreasonable barriers for food product research.

POM Wonderful Asks Court To Vacate “Draconian” FTC Order

The nearly three-year battle between FTC and POM Wonderful moves to a federal appeals court, where the pomegranate juice and supplement firm asks the judges to nix the commission’s order that POM conduct two randomized controlled trials to support disease-related health claims.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel